4//SEC Filing
Matrix Capital Management Company, LP 4
Accession 0000902664-23-003642
CIK 0001725160other
Filed
Jun 19, 8:00 PM ET
Accepted
Jun 20, 4:30 PM ET
Size
7.7 KB
Accession
0000902664-23-003642
Insider Transaction Report
Form 4
GOEL DAVID E.
Director10% Owner
Transactions
- Purchase
Common Stock, par value $0.001 per share
2023-06-20$22.66/sh+4,760,000$107,861,600→ 13,959,973 total(indirect: See footnotes)
Matrix Capital Management Company, LP
Director10% OwnerOther
Transactions
- Purchase
Common Stock, par value $0.001 per share
2023-06-20$22.66/sh+4,760,000$107,861,600→ 13,959,973 total(indirect: See footnotes)
Footnotes (2)
- [F1]The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.
- [F2]The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
Documents
Issuer
Zentalis Pharmaceuticals, Inc.
CIK 0001725160
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001410830
Filing Metadata
- Form type
- 4
- Filed
- Jun 19, 8:00 PM ET
- Accepted
- Jun 20, 4:30 PM ET
- Size
- 7.7 KB